Current Report Filing (8-k)

Date : 06/28/2018 @ 11:09AM
Source : Edgar (US Regulatory)
Stock : MabVax Therapeutics Holdings, Inc. (MBVXQ)
Quote : 0.0222  0.0 (0.00%) @ 8:14PM

Current Report Filing (8-k)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): June 21, 2018
 
 
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
  
Delaware
 
000-37861
 
93-0987903
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (858) 259-9405
 
N/A
(Former name or former address, if changed since last report.)
  
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company [ ]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
 
 

 
 
 
 
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
 
As previously disclosed in a Current Report on Form 8-K filed on May 21, 2018, MabVax Therapeutics Holdings, Inc., (“we”, “us”, or the “Company”) notified the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that we would not be timely filing our Quarterly Report on Form 10-Q for the period ended March 31, 2018 (the “Form 10-Q”) as required for continued listing on Nasdaq, in accordance with Nasdaq Listing Rule 5250(c)(1). As previously disclosed in the May 21, 2018 Current Report, on May 21, 2018 we received a letter from the Staff (the “May 21, 2018 Letter”) issued pursuant to Nasdaq Listing Rule 5810(c)(2) stating that, due to the delay in filing the Form 10-Q, we were no longer in compliance with Nasdaq Listing Rule 5250(c)(1), and that we had been granted 60 calendar days from the date of the May 21, 2018 Letter to submit a plan to regain compliance with the filing requirement (the “Plan”).
 
On June 21, 2018, we received a second letter from the Staff superseding the May 21, 2018 Letter (the “Superseding Letter”). Per the Superseding Letter, the Staff determined to apply more stringent criteria and to shorten the time period for the Company to submit its Plan from 60 days to a new due date of June 28, 2018 pursuant to Nasdaq’s discretionary authority set forth in Nasdaq Listing Rule 5101. The reason for the acceleration of this due date, according to the Superseding Letter, was based upon the Company’s continued delay in filing the Form 10-Q and the disclosure that the Company’s independent auditor withdrew its audit reports included in the Forms 10-K for the years ended December 31, 2014, through 2017 included in the May 21, 2018 Current Report.
 
If the Staff accepts our Plan, the Staff may grant us a grace period of up to 180 calendar days from the original due date to file the Form 10-Q to regain compliance, or until November 12, 2018. There can be no assurance that we will present a Plan acceptable to the Staff or that we will be able to file the Form 10-Q within an extension of time that may be granted by the Staff.
 
Item 8.01
Other Events.
 
In accordance with the terms of the Superseding Letter, on June 27, 2018, the Company issued a press release disclosing receipt of the Superseding Letter and the above terms of the Superseding Letter. A copy of the press release is furnished as Exhibit 99.1 to this Report.
 
In accordance with General Instruction B.2 of Form 8-K, the press release is deemed to be “furnished” and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
 
Forward-Looking Statements
 
The foregoing includes statements that constitute “forward-looking” statements, as such term is defined in the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “plan,” or the negative of those terms or other comparable terminology. These forward-looking statements are subject to the safe harbor protection provided by the federal securities laws. These forward-looking statements are subject to numerous risks, uncertainties and assumptions. These risks and uncertainties include, but are not limited to, the ability of the Company to timely file its periodic Exchange Act reports, the ability of the Company to regain and maintain compliance with Nasdaq continued listing requirements and the risk factors described in our Annual Report on Form 10-K filed on April 2, 2018. Because these forward-looking statements are subject to risks and uncertainties, actual developments and results may differ materially from those express or implied by the forward-looking statements. The forward-looking statements in this filing are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
 
Item 9.01
Financial Statements and Exhibits.
 
The following exhibit is furnished as part of this Current Report on Form 8-K:
 
P ress Release, dated June 27, 2018.
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
MABVAX THERAPEUTICS HOLDINGS, INC.
 
 
 
 
Dated: June 27, 2018
 
 
 
/s/ J. David Hansen
 
 
 
 
J. David Hansen
 
 
 
 
President and Chief Executive Officer
 
  
 
 
 

MabVax Therapeutics Holdings, (USOTC:MBVXQ)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more MabVax Therapeutics Holdings, Charts.

MabVax Therapeutics Holdings, (USOTC:MBVXQ)
Intraday Stock Chart

Today : Monday 22 July 2019

Click Here for more MabVax Therapeutics Holdings, Charts.

Latest MBVXQ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.